WCLC, TORONTO, 23-26 September 2018

Named patient use program for afatinib in advanced NSCLC with progression on prior therapy: experience from Asian centers

Gee-Chen Chang, Chi Leung Lam, Chun-Ming Tsai, Yuh-Min Chen, Jin-Yuan Shih, Shyam Aggarwal, Shuhang Wang, Sang-We Kim, Young-Chul Kim, Ibrahim Wahid, Rubi Li, Wan-Teck Lim, Virote Sriuranpong, Tsz Tong Chan, Robert M. Lorence, Philippe Carriere, Christina Raabe, Agnieszka Cseh, Keunchil Park

Chang et al_Asian NPU_WCLC 2018


Learn more about the science behind this poster in the videos, papers and other materials below.

Global named patient use program of afatinib in advanced non-small-cell lung carcinoma patients who progressed following prior therapies.

Cappuzzo F, et al. Future Oncol. 2018 Jun;14(15):1477-1486.

Activity of afatinib in heavily pre-treated patients with HER2 mutation-positive advanced NSCLC: findings from a global NPU programme

Peters S, et al. ESMO 2017 Poster Landing Page (Inoncology.com)


In the European Union, afatinib is approved for use in TKI-naive adults with locally advanced or metastatic NSCLC with activating EGFR mutations and in patients with NSCLC of squamous histology on or after chemotherapy. It is not yet approved in other indications.

In Switzerland, Afatinib is approved as monotherapy for patients with non-small cell lung cancer (NSCLC, stage IIIb/IV) with activating mutations of EGFR (exon 19 deletions or exon 21 L858R substitutions), not previously treated with EGFR TKIs. It is also indicated for the treatment of patients with locally advanced or metastatic squamous cell cancer of the lung whose carcinoma progressed during or after platinum-based chemotherapy and for whom immunotherapy is not suitable.

The information contained herein does not necessarily reflect the content of the approved Canadian product monograph.